Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study - Leiter, L A; Carr, M C; Stewart, M (Diabetes Care, 2014)
et al.